HOWL — Werewolf Therapeutics Cashflow Statement
0.000.00%
Last trade - 00:00- $53.39m
- $2.90m
- $1.89m
Annual cashflow statement for Werewolf Therapeutics, fiscal year end - December 31st, USD millions except per share, conversion factor applied.
2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | 2024 December 31st | |
|---|---|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
| Source: | PROSPECTUS | 10-K | 10-K | 10-K | 10-K |
| Standards: | USG | USG | USG | USG | USG |
| Status: | Final | Final | Final | Final | Final |
| Net Income/Starting Line | -15 | -50 | -53.8 | -37.4 | -70.5 |
| Depreciation | |||||
| Non-Cash Items | -6.04 | 4.61 | 9.57 | 8.89 | 9.99 |
| Unusual Items | |||||
| Other Non-Cash Items | |||||
| Changes in Working Capital | 2.31 | 2.28 | 2.54 | -5.89 | 2.53 |
| Change in Accounts Receivable | |||||
| Change in Prepaid Expenses | |||||
| Change in Other Assets | |||||
| Change in Accounts Payable | |||||
| Change in Accrued Expenses | |||||
| Change in Other Liabilities | |||||
| Cash from Operating Activities | -18.6 | -42.9 | -40.6 | -32.6 | -56.2 |
| Capital Expenditures | -0.56 | -0.498 | -3.61 | -0.769 | -0.254 |
| Purchase of Fixed Assets | |||||
| Cash from Investing Activities | -0.56 | -0.498 | -3.61 | -0.769 | -0.254 |
| Financing Cash Flow Items | -0.339 | -2.38 | -0.539 | 0 | -0.673 |
| Other Financing Cash Flow | |||||
| Net Issuance / Retirement of Stock | |||||
| Net Issuance / Retirement of Debt | |||||
| Cash from Financing Activities | 93.9 | 109 | 15.9 | 58.4 | 13.1 |
| Beginning Cash Balance | |||||
| Ending Cash Balance | |||||
| Net Change in Cash | 74.7 | 66.1 | -28.3 | 25 | -43.4 |